Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).

@article{Cheng2011PhaseIT,
  title={Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).},
  author={Ann-lii Cheng and Yoon-koo Kang and D Lin and Joong-Won Park and Masatoshi Kudo and Shukui Qin and Masao Omata and Susan Pitman Lowenthal and Silvana Lanzalone and Liqiang Yang and Mariajos{\'e} Lechuga and Eric Raymond},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4000}
}
4000 Background: The oral multitargeted tyrosine kinase inhibitor Su had antitumor activity in phase II HCC trials, leading to a phase III open-label trial comparing the efficacy and safety of Su with So. METHODS Patients (pts) with advanced HCC, Child-Pugh A, ECOG PS 0/1 and no prior systemic chemotherapy were stratified by geographic region, prior TACE and tumor invasion. Pts were randomized 1:1 to Su 37.5 mg/day or So 400 mg BID. The primary endpoint was overall survival (OS; 1-sided log… CONTINUE READING
58 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…